INNOVENT BIO has reached a BD Trade with Roche. After the suspicion of 'undervaluing,' Fortvita appears as the signing party | Quick announcement.

① INNOVENT BIO has reached a global exclusive licensing agreement for the next-generation anti-DLL3 antibody-drug conjugate (IBI3009) with Roche Pharmaceuticals; ② Industry insiders state that the Trade amount is "moderate and not particularly stunning"; ③ After experiencing turmoil with overseas Assets, ortvita Biologics (Singapore) appears as a signatory in this Trade agreement.

cls.cnJan 2 19:25

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

So sudden! What happened with the well-known Hong Kong stocks in a collective turmoil?

In today's morning session, the Hong Kong stock market suddenly experienced a significant decline, with all three major Indexes dropping by more than 2%.

Brokerage ChinaJan 2 12:20

Not just a simple "split": The multifaceted considerations behind the sale of WUXI APPTEC's CGT Business.

In an era where Globalization and protectionism coexist, the rapid iteration of cutting-edge technologies, alongside multiple constraints from policies and capital, poses unprecedented challenges for pharmaceutical innovation companies.

wallstreetcnJan 2 08:50

At the end of the year, Jiangsu Hengrui Pharmaceuticals has made another achievement in business development, with an ADC new drug receiving a first payment of 75 million USD | Quick read of the announcement.

① This evening, Jiangsu Hengrui Pharmaceuticals announced that the overseas rights for the DLL3 ADC innovative drug SHR-4849 have been granted to USA's IDEAYA Biosciences, resulting in a payment of 75 million USD as an upfront fee; ② Jiangsu Hengrui Pharmaceuticals is accelerating its international development. Previously, Sun Piaoyang stated: going abroad is a path we must take, and how to do it steadily and successfully is a question we continue to explore.

cls.cnDec 29, 2024 20:36

Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.

There is gain in loss.

wallstreetcnDec 25, 2024 10:26